Currently, there are 16.67M common shares owned by the public and among those 16.09M shares have been available to trade.
The company’s stock has a 5-day price change of 17.78% and 35.64% over the past three months. ASLN shares are trading 31.20% year to date (YTD), with the 12-month market performance down to -75.97% lower. It has a 12-month low price of $0.39 and touched a high of $4.69 over the same period. ASLN has an average intraday trading volume of 655.16K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.16%, 12.58%, and -59.01% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of ASLAN Pharmaceuticals Ltd ADR (NASDAQ: ASLN) shares accounts for 20.89% of the company’s 16.67M shares outstanding.
It has a market capitalization of $11.42M and a beta (3y monthly) value of 1.44. The earnings-per-share (ttm) stands at -$3.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 93.25% over the week and 34.47% over the month.
Analysts forecast that ASLAN Pharmaceuticals Ltd ADR (ASLN) will achieve an EPS of -$0.65 for the current quarter, -$0.63 for the next quarter and -$4.25 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.65 while analysts give the company a high EPS estimate of -$0.65. Comparatively, EPS for the current quarter was -$1.04 a year ago. Earnings per share for the fiscal year are expected to increase by 29.08%, and -62.84% over the next financial year.
Looking at the support for the ASLN, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on July 09, 2021, with the firm’s price target at $8. H.C. Wainwright coverage for the ASLAN Pharmaceuticals Ltd ADR (ASLN) stock in a research note released on January 14, 2019 offered a Buy rating with a price target of $8.50.
